scholarly journals Survival of Group A Erythrocytes Following Bone Marrow Transplantation for Reconstitution of Lymphopenic Hypogammaglobulinemia

Blood ◽  
1971 ◽  
Vol 38 (1) ◽  
pp. 60-65 ◽  
Author(s):  
M. M. AZAR ◽  
R. A. GATTI ◽  
E. J. YUNIS ◽  
J. SWANSON ◽  
R. A. GOOD
Keyword(s):  
Bone Marrow ◽  
Immune System ◽  
Bone Marrow Transplantation ◽  
Blood Group ◽  
Marrow Transplantation ◽  
Bone Marrow Transplants ◽  
Blood Group A ◽  
Group A ◽  
Immunological Destruction

Abstract The survival of chromium-labeled group A erythrocytes was measured in a patient who had previously received two bone marrow transplants for reconstitution of lymphopenic hypogammaglobulinemia. The patient was of blood group A before transplantation; the donor of blood group O. The patient’s erythrocytes are now virtually 100% group O. Anti-B titers are present; anti-A antibodies are not demonstrable. The cells producing these isohemagglutinins are of donor origin; the donor has anti-A titers of 1:64 in saline and 1:256 by antihuman globulin test as well as anti-B titers. No evidence of immunological destruction of group A erythrocytes was found in this patient suggesting that the immune system of the donor may have become tolerant of the group A substance of the recipient.

scholarly journals Plasma blood group glycosyltransferase activities after bone marrow transplantation

Blood ◽  
1980 ◽  
Vol 55 (4) ◽  
pp. 699-701 ◽  
Author(s):  
A Yoshida ◽  
GM Schmidt ◽  
KG Blume ◽  
E Beutler
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Cell Surface ◽  
Blood Group ◽  
Marrow Transplantation ◽  
Primary Source ◽  
Blood Type ◽  
Red Cell ◽  
Complete Replacement ◽  
Group B

Human blood groups (ABO) are known to be determined by the terminal glycosyl residues attached to common carbohydrate chains of the red cell surface. N-acetylgalactosaminyltransferase (A-enzyme) in blood group A persons and galactosyltransferase (B-enzyme) in blood group B persons are responsible for producing A and B substances on the red cell surface, with both enzymes absent in blood group O persons. The plasma transferase (A - and B-) activity was assayed after the complete replacement of the bone marrow of patients with acute leukemia or aplastic anemia by transplantation bone marrow from donors with ABO blood group differing from the recipient. The patient's blood type completely changed from the recipient's type to the donor's type. However, the A- and B-enzyme activities of the patients changed only slightly after bone marrow transplantation. The results indicate that most of the A- and B-enzymes in the circulatory plasma is not derived from the bone marrow, lymphoid, or macrophage tissue. Other tissues must be the primary source of the enzymes in plasma.

scholarly journals Plasma blood group glycosyltransferase activities after bone marrow transplantation

Blood ◽  
1980 ◽  
Vol 55 (4) ◽  
pp. 699-701 ◽  
Author(s):  
A Yoshida ◽  
GM Schmidt ◽  
KG Blume ◽  
E Beutler
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Cell Surface ◽  
Blood Group ◽  
Marrow Transplantation ◽  
Primary Source ◽  
Blood Type ◽  
Red Cell ◽  
Complete Replacement ◽  
Group B

Abstract Human blood groups (ABO) are known to be determined by the terminal glycosyl residues attached to common carbohydrate chains of the red cell surface. N-acetylgalactosaminyltransferase (A-enzyme) in blood group A persons and galactosyltransferase (B-enzyme) in blood group B persons are responsible for producing A and B substances on the red cell surface, with both enzymes absent in blood group O persons. The plasma transferase (A - and B-) activity was assayed after the complete replacement of the bone marrow of patients with acute leukemia or aplastic anemia by transplantation bone marrow from donors with ABO blood group differing from the recipient. The patient's blood type completely changed from the recipient's type to the donor's type. However, the A- and B-enzyme activities of the patients changed only slightly after bone marrow transplantation. The results indicate that most of the A- and B-enzymes in the circulatory plasma is not derived from the bone marrow, lymphoid, or macrophage tissue. Other tissues must be the primary source of the enzymes in plasma.

Failure of allogeneic bone marrow transplantation to arrest disease activity in multiple sclerosis

2007 ◽  
Vol 13 (8) ◽  
pp. 1071-1075 ◽  
Author(s):  
D.R. Jeffery
Keyword(s):  
Multiple Sclerosis ◽  
Bone Marrow ◽  
Immune System ◽  
Bone Marrow Transplantation ◽  
Autoimmune Disease ◽  
Disease Activity ◽  
Marrow Transplantation ◽  
Myelogenous Leukemia ◽  
Allogeneic Bone ◽  
Immune Mediated

Multiple sclerosis (MS) is thought to be an autoimmune disease in which activated T-cells initiate a macrophage mediated destruction of CNS myelin. Bone marrow transplantation (BMT) is currently being evaluated in the treatment of MS in patients with aggressive disease activity. Autologous BMT could potentially reset the immune response to myelin antigens leading to immune tolerance and decreased disease activity. Allogeneic transplantation could reconstitute the immune system potentially arresting the progression of autoimmune disease. The purpose of this paper is to report a patient with MS who underwent allogeneic BMT for chronic myelogenous leukemia (CML) and showed continued evidence of active demyelinating disease by clinical and radiologic criteria over a period of two years. While this is only a single case report with inherent limitations, it suggests that the immune mediated destruction of CNS myelin in MS may not be prevented or aborted by immune system reconstitution, and is consistent with the idea that immune mediated tissue destruction in MS could be targeted against an abnormal antigen. Multiple Sclerosis 2007; 13: 1071—1075. http://msj.sagepub.com

RECOVERY OF HEMATOPOIESIS AFTER BLOOD-GROUP-INCOMPATIBLE BONE MARROW TRANSPLANTATION WITH RED-BLOOD-CELL-DEPLETED GRAFTS

1985 ◽  
Vol 39 (5) ◽  
pp. 514-519 ◽  
Author(s):  
J. H. F. FALKENBURG ◽  
M. R. SCHAAFSMA ◽  
J. JANSEN ◽  
A. BRAND ◽  
H. M. GOSELINK ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Blood Cell ◽  
Blood Group ◽  
Red Blood Cell ◽  
Marrow Transplantation

scholarly journals Bone marrow transplantation for Fanconi anemia

Blood ◽  
1995 ◽  
Vol 86 (7) ◽  
pp. 2856-2862 ◽  
Author(s):  
E Gluckman ◽  
AD Auerbach ◽  
MM Horowitz ◽  
KA Sobocinski ◽  
RC Ash ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Fanconi Anemia ◽  
Marrow Transplantation ◽  
Bone Marrow Failure ◽  
Unrelated Donor ◽  
Bone Marrow Transplants ◽  
Transplant Outcome ◽  
Factors Associated ◽  
Increased Risk

Fanconi anemia is a genetic disorder associated with diverse congenital abnormalities, progressive bone marrow failure, and increased risk of leukemia and other cancers. Affected persons often die before 30 years of age. Bone marrow transplantation is an effective treatment, but there are few data regarding factors associated with transplant outcome. We analyzed outcomes of HLA-identical sibling (N = 151) or alternative related or unrelated donor (N = 48) bone marrow transplants for Fanconi anemia performed between 1978 and 1994 and reported to the International Bone Marrow Transplant Registry. Fanconi anemia was documented by cytogenetic studies in all cases. Patient, disease, and treatment factors associated with survival were determined using Cox proportional hazards regression. Two-year probabilities (95% confidence interval) of survival were 66% (58% to 73%) after HLA-identical siblings transplants and 29% (18% to 43%) after alternative donor transplants. Younger patient age (P .0001), higher pretransplant platelet counts (P = .04), use of antithymocyte globulin (P = .005), and use of low-dose (15 to 25 mg/kg) cyclophosphamide plus limited field irradiation (P = .009) for pretransplant conditioning and cyclosporine for graft-versus-host disease prophylaxis (P = .002) were associated with increased survival. Bone marrow transplants are effective therapy for Fanconi anemia. The adverse impact of increasing age and lower pretransplant platelet count on transplant outcome favors earlier intervention, especially when there is an HLA-identical sibling donor.

scholarly journals A controlled trial of recombinant human erythropoietin after bone marrow transplantation

Blood ◽  
1994 ◽  
Vol 84 (10) ◽  
pp. 3327-3335
Author(s):  
H Link ◽  
MA Boogaerts ◽  
AA Fauser ◽  
S Slavin ◽  
J Reiffers ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Blood Group ◽  
Marrow Transplantation ◽  
Recombinant Human Erythropoietin ◽  
Abo Blood Group ◽  
Allogeneic Bmt ◽  
Human Erythropoietin ◽  
Transfusion Independence ◽  
Transfusion Requirements

Recombinant human erythropoietin (rHuEPO) stimulates erythropoietic bone marrow cells and increases erythrocyte production. This prospective study was designed to evaluate the effects of rHuEPO on regeneration of erythropoiesis after allogeneic or autologous bone marrow transplantation (BMT). Seventeen centers participated in this randomized, double-blind, placebo-controlled multicenter trial. The randomization was performed centrally for each center and stratified according to allogeneic or autologous BMT and major ABO-blood group incompatibility. One hundred and six patients received rHuEPO after allogeneic BMT and 109 patients received placebo. After autologous BMT, 57 patients were treated with rHuEPO and 57 with placebo. Patients received either 150 IU/kg/day C127 mouse-cell-derived rHuEPO or placebo as continuous intravenous infusion. Therapy started after bone marrow infusion and lasted until independence from erythrocyte transfusions for 7 consecutive days with stable hemoglobin levels > or = 9 g/100 mL or until day 41. After allogeneic BMT, the reticulocyte counts were significantly higher with rHuEPO from day 21 to day 42 after BMT. The median time (95% confidence intervals) to erythrocyte transfusion independence was 19 days (range, 16.3 to 21.6) with rHuEPO and 27 days (range, 22.3 to > 42) with placebo (P < .003). The mean (+/- SD) numbers of erythrocyte transfusions until day 20 after BMT were 6.6 +/- 4.8 with rHuEPO and 6.0 +/- 3.8 with placebo. However, from day 21 to day 41, the rHuEPO-treated patients received 1.4 +/- 2.5 (median, 0) transfusions and the control group received 2.7 +/- 4.0 (median, 2) transfusions (P = .004). In the follow-up period from day 42 up to day 100, 2.4 +/- 5.6 transfusions were required with rHuEPO and 4.5 +/- 9.6 were required with placebo (P = .075). A multivariate analysis (ANOVA) showed that acute graft-versus-host disease (GVHD), major ABO-blood group incompatibility, age greater than 35 years, and hemorrhage significantly increased the number of transfusions. However, after day 20, rHuEPO significantly reduced the number of erythrocyte transfusions in these patient groups, as well as reducing incompatibility in the major ABO-blood group. For the whole study period, rHuEPO reduced the transfusion requirements in GVHD III and IV from 18.4 +/- 8.6 to 8.5 +/- 6.8 U (P = .05). After autologous BMT, there was no difference in the time to independence from erythrocyte transfusions and in the regeneration of reticulocytes. Marrow purging strongly increased the requirement for transfusions as well as the time to transfusion independence.

scholarly journals Blood group A is a negative risk factor for peripheric blood stem cell mobilization in allogeneic donors

2020 ◽  
Vol 7 (6) ◽  
pp. 505-508
Author(s):  
Tuğçe Nur Yigenoğlu ◽  
Mehmet Bakırtaş ◽  
Semih Başcı ◽  
Bahar Uncu Ulu ◽  
Derya Şahin ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Risk Factor ◽  
Stem Cell ◽  
Blood Group ◽  
Blood Groups ◽  
Bone Marrow Niche ◽  
Blood Group A ◽  
Healthy Donors ◽  
Cd34 Cells ◽  
Group A

Objective: Many factors, including advanced age and female gender, have been identified as negative factors for peripheric blood hematopoietic stem cell (HSC) mobilization. Similarly, blood group antigens may have an effect on the release of HSCs from the bone marrow niche into the periphery. We aimed to study the effect of ABO and Rh blood groups on peripheral blood HSC mobilization in healthy donors. Material and Method: The data of 314 healthy donors who underwent peripheric blood HSC mobilization in our center were analyzed retrospectively. Results: The number of CD34+ cells collected on the first day and in total was the least in donors with blood group A. A statistically significant relation was found between ABO blood groups and the number of CD34+ cells collected on the first day and in total. No relation was found between Rh positivity and the number of CD34+ cells collected. Conclusion: According to our research in the literature, this is the first study that investigates whether blood groups have an effect on the release of HSCs from the bone marrow niche into the periphery and we observed that blood group A is a negative risk factor for peripheric blood HSC mobilization.

Sign in / Sign up

Export Citation Format

Share Document